HDL as a Biomarker, Potential Therapeutic Target, and Therapy
- Mohamad Navab1,
- G.M. Anantharamaiah2,
- Srinivasa T. Reddy1,
- Brian J. Van Lenten1 and
- Alan M. Fogelman1
- 1Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California;
- 2Atherosclerosis Research Unit, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
- Corresponding author: Mohamad Navab, mnavab{at}mednet.ucla.edu.
Article Figures & Tables
Figures
- FIG. 1.
HII in diabetes. Abn'l GTT, abnormal oral glucose tolerance test.
In this Issue
December 2009, 58(12)
HDL as a Biomarker, Potential Therapeutic Target, and Therapy
